Literature DB >> 17341725

Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.

Rabiya S Tuma.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17341725     DOI: 10.1093/jnci/djk122

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  5 in total

1.  An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.

Authors:  Zachary C Hartman; Junping Wei; Takuya Osada; Oliver Glass; Gangjun Lei; Xiao-Yi Yang; Sharon Peplinski; Dong-Wan Kim; Wenle Xia; Neil Spector; Jeffrey Marks; William Barry; Amy Hobeika; Gayathri Devi; Andrea Amalfitano; Michael A Morse; H Kim Lyerly; Timothy M Clay
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel.

Authors:  Guenther G Steger; Jitka Abrahámová; Florin Bacanu; Stephen Brincat; Arija Brize; Alvydas Cesas; Tanja Cufer; Magdolna Dank; Renata Duchnowska; Alexandru Eniu; Jacek Jassem; Zsuzsanna Kahán; Erika Matos; Peeter Padrik; Signe Plāte; Helis Pokker; Gunta Purkalne; Constanta Timcheva; Valentina Tzekova; Rostislav Vyzula; Christoph C Zielinski
Journal:  Wien Klin Wochenschr       Date:  2010-06-15       Impact factor: 1.704

Review 3.  Lapatinib: a sword with two edges.

Authors:  László Kopper
Journal:  Pathol Oncol Res       Date:  2008-04-12       Impact factor: 3.201

4.  Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.

Authors:  Renan B Ferreira; Mengxiong Wang; Mary E Law; Bradley J Davis; Ashton N Bartley; Paul J Higgins; Michael S Kilberg; Katherine E Santostefano; Naohiro Terada; Coy D Heldermon; Ronald K Castellano; Brian K Law
Journal:  Oncotarget       Date:  2017-04-25

5.  Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer.

Authors:  Elizabeth S Henson; James B Johnston; Marek Los; Spencer B Gibson
Journal:  Biologics       Date:  2007-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.